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Abstract
A causative understanding of genetic factors that regulate glioblastoma (GBM) pathogenesis is of 
central importance. Here, we developed an adeno-associated virus (AAV)-mediated autochthonous 
CRISPR screen in GBM. Stereotaxic delivery of an AAV library targeting genes commonly 
mutated in human cancers into the brains of conditional Cas9 mice resulted in tumors that 
recapitulate human GBM. Capture sequencing revealed diverse mutational profiles across tumors. 
The mutation frequencies in mice correlate with those in two independent patient cohorts. Co-
mutation analysis identified co-occurring driver combinations such as Mll2, B2m-Nf1, Mll3-Nf1 
and Zc3h13-Rb1, which were subsequently validated using AAV minipools. Distinct from Nf1-
mutant tumors, Rb1-mutant tumors are undifferentiated and aberrantly express Homeobox gene 
clusters. The addition of Zc3h13 or Pten mutations altered the gene expression profiles of Rb1 
mutants, rendering them more resistant to temozolomide. Our study provides a functional 
landscape of gliomagenesis suppressors in vivo.
Introduction
Glioblastoma (Glioblastoma multiforme, GBM) is one of the deadliest cancers1. Current 
standard of care fails to cure the vast majority of patients with this disease1–3, leaving them a 
median survival of 12.2 to 18.2 months4–7. The first genome atlas of GBM uncovered 453 
validated non-silent somatic mutations in 223 unique genes, which were further refined to a 
total of 71 significantly mutated genes (SMGs)8. Subsequent integrative genomic analyses 
revealed comprehensive mutational landscapes in GBM, uncovering 21 to 75 SMGs across 
multiple different cohorts of patients8–13. Many of the newly discovered genes have never 
been characterized in GBM; thus, their functional roles in gliomagenesis remain largely 
unknown9, 10. Further complicating the interpretation of causality, mutations can occur in 
novel combinations across individual patients, leading to drastically different pathological 
features, prognoses, and therapeutic responses3, 14–16. Thus, a deeper functional 
understanding of gliomagenesis and a quantitative measurement of phenotypic effects across 
various combinations of drivers are both of central importance.
To date, no study has comprehensively and combinatorially investigated which of the 
mutations identified in human patients can indeed functionally drive GBM from normal cells 
in the brain9. Key barriers include accurate delivery, precise genome manipulation, efficient 
massively parallel perturbation, and unbiased, high-sensitivity quantitative readout, all of 
which have to be achieved simultaneously in the native brain microenvironment. We 
overcame these challenges through an AAV-mediated direct in vivo autochthonous CRISPR 
screen in the brain of fully immunocompetent mice, coupled with capture sequencing to 
achieve an ultra-deep readout of all functional variants. With these data, we identified 
multiple new drivers and co-occurring drivers, and subsequently validated a set of such 
combinations. Transcriptome profiling of these driver combinations revealed distinct 
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expression signatures between genotypes and in response to temozolomide (TMZ) 
treatment. Utilizing this approach, we mapped the functional landscape of GBM suppressors 
in the native microenvironment of the mouse brain.
Results
Stereotaxic injection of an AAV-CRISPR library drives robust gliomagenesis
To directly test the function of putative SMGs in the mouse brain, we set out to develop a 
direct in vivo autochthonous screening strategy, which necessitates pooled mutagenesis of 
normal cells directly in the native organ and subsequent deconvolution of mutant 
phenotypes. Because GBM is a disease originating from astrocytes, we generated an AAV-
CRISPR vector that encodes Cre recombinase under a Glial fibrillary acidic protein (GFAP) 
promoter, resulting in conditional expression of Cas9 and GFP in astrocytes when injected 
into a conditional Rosa26-LSL-Cas9-GFP mouse (LSL-Cas9 mouse) (Methods) (Figure 
S1a). The vector also contains an sgRNA targeting Trp53, with the initial intent to generate 
co-mutational Trp53 knockouts that might exhibit genome instability and thus be sensitized 
to tumorigenesis17–21. Local viral delivery into the brain restricts the number of transducible 
cells, and cancer genomes generally consist of dozens to hundreds of SMGs22–25. With these 
considerations in mind, we designed an sgRNA library (mTSG library) targeting the mouse 
homologs of top-ranked pan-cancer SMGs (Methods), plus 7 genes with essential molecular 
functions that we initially considered as internal controls (Figure 1a) (Table S1). We pool-
synthesized all sgRNAs, cloned them into the AAV-CRISPR vector at greater than 100× 
coverage, and deep-sequenced the library to ensure all sgRNAs were fully covered and 
represented with a tight lognormal distribution (99% within two orders of magnitude) 
(Figure 1a, Figure S1b). We generated high-titer AAVs (> 1 * 1012 viral particles per mL) 
from the plasmid that contained the mTSG library (AAV-mTSG), as well as the empty 
vector (AAV-vector) (Figure 1a). We then stereotaxically injected AAV-mTSG, AAV-vector 
or PBS into the lateral ventricle (LV, n = 40 mice) or hippocampus (HPF, n = 16 mice) in the 
brains of LSL-Cas9 mice (Methods). We performed magnetic resonance imaging (MRI) to 
scan the brains of these mice at four-months post-injection, and found that half (9/18 = 50%) 
of AAV-mTSG library transduced animals developed brain tumors at this time point, 
whereas none of the AAV-vector or PBS injected animals had detectable tumors by MRI 
(Figure 1b) (Figure S1e) (Table S2). Quantification of tumor volumes showed that AAV-
mTSG transduced mice had average tumor volumes of 70.2 mm3 (including animals without 
tumors), or 140.3 mm3 (excluding animals without a tumor) (two-tailed Welch’s t-test, t17 = 
2.62, p = 0.018, mTSG vs. vector or PBS) (Figure 1c) (Table S2). These data suggested that 
the AAV-mTSG library robustly initiated tumorigenesis in the brains of LSL-Cas9 mice.
We analyzed the overall survival of a cohort of LSL-Cas9 mice injected with AAV-mTSG, 
AAV-vector or PBS (Table S3). In this screen, injection location did not affect the rate of 
tumor development as reflected by overall survival (two-sided Mann-Whitney U test of HPF 
vs LV, p = 0.054) (Table S3), and thus were considered as one group (AAV-mTSG). For the 
AAV-mTSG transduced group, the first three animals died 84 days post injection (dpi), 90% 
of animals did not survive 176 dpi, and all 56 AAV-mTSG transduced animals reached their 
survival endpoints within 299 days (i.e. died, or had a poor body condition score BCS < 2, 
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and thus were euthanized) (Table S3) (Figure 1d). The median survival time of the AAV-
mTSG group was 129 days (95% confidence interval (CI) = 111–159 days) (Figure 1d), 
consistent with the presence of tumors in half of the mice at 4 months by MRI. In contrast, 
all 24 AAV-vector and all 5 PBS injected animals survived the duration of the study and 
maintained good body condition (BCS = 5) (log-rank (LR) test, p < 2.2 * 10−16, mTSG vs. 
vector or PBS; LR test, p = 1, vector vs PBS) (Figure 1d). For the vast majority (96.4%, or 
54/56) of AAV-mTSG injected mice, macrocephaly was observed at the survival endpoint 
(Figure S1c), suggesting that they had developed brain tumors. On the contrary, 
macrocephaly was observed in none of the AAV-vector (0/24) or PBS (0/5) injected mice 
during the study (two-tailed Fischer’s exact test, p < 1 * 105, mTSG vs. vector or PBS; p = 
1, vector vs. PBS). These data indicated that the brain tumors induced by the AAV-mTSG 
viral library were typically lethal.
We observed that AAV-mTSG mice had GFP-positive masses that deformed their brains 
(100%, or 6/6) (Figure S1d, Figure 2a). AAV-vector mice had diffuse GFP-positive regions 
in the brain with fully normal morphology, suggesting these were AAV-transduced cells 
expressing Cas9-GFP induced by Cre expression that had not become tumors (n = 2) (Figure 
S1d, Figure 2a). PBS injected or uninjected mice had no detectable GFP expression even at 
long exposure (n = 3) (Figure S1d). Immunohistochemistry (IHC) analysis showed that 
AAV-mTSG induced tumors stained positive for Cas9 and GFP, consistent with them having 
arisen from cells with activation of Cas9-GFP expression (Figure 2a). These tumors were 
also positive for GFAP, an astrocytic marker (Figure 2a), and for Ki67, a proliferation 
marker (Figure 2a). AAV-vector transduced brains stained positive for Cas9 and GFP in a 
subset of cells at the injection site (Figure 2a), but these cells were not proliferative (Ki67 
negative) and did not have tumor-like pathological features (Figure 2a). PBS-injected mice 
stained negative for Cas9, GFP and Ki67 (Figure 2a). Endpoint histopathology showed that 
the vast majority of AAV-mTSG mice developed brain tumors (10/11 = 91%), whereas none 
of AAV-vector (0/7 = 0%) or PBS (0/3 = 0%) mice had detectable tumors (two-tailed 
Fischer’s exact test: p = 0.0003, mTSG vs. vector; p = 0.011, mTSG vs. PBS) (Figure 2a–b) 
(Table S4). The mean endpoint tumor size as measured by area in brain sections for the 
AAV-mTSG group was 13.9 mm2, as compared to 0 mm2 in the two control groups (two-
tailed Welch’s t-test, t10 = 3.97, p = 0.003, mTSG vs. vector or PBS) (Figure 2b). Brain 
tumors in AAV-mTSG mice showed pathological features of dense cellular structure with 
proliferative spindles, nuclear aneuploidy and pleiomorphism, giant cells, regions of 
necrosis, angiogenesis and hemorrhage (Figure 2c), all of which are hallmark features of 
human GBM2. Clinical features such as deformation of the brain, invasion, loss of neuronal 
bundles, necrosis and hemorrhage were further corroborated by special staining methods 
such as Luxol fast blue Cresyl violet (LFB/CV), Wright Giemsa, Masson and Alcian Blue 
Periodic acid – Schiff (AB/PAS) (Figure S2). We investigated a panel of human GBM 
clinical samples from Yale Glioma tissue bank, and confirmed the observation of these 
pathological features (Figure S3a–b). These data suggested that the AAV-mTSG library-
induced autochthonous brain tumors recapitulate features of human GBM.
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Targeted capture sequencing reveals diverse mutational profiles across tumors
Because AAVs usually do not integrate into the genome, direct sequencing of the targeted 
regions was needed to determine which mutations were in each tumor. To map the molecular 
landscape of these brain tumors, we designed a probe set (mTSG-Amplicon probes) 
covering the target regions of all library sgRNAs (Methods) (Table S5). We used these 
probes to perform targeted capture sequencing for whole brain and liver samples (as a 
control organ not being directly transduced) in a cohort of AAV-mTSG, AAV-vector and 
PBS injected mice (n = 25, 3, and 4 brain samples, respectively) (Table S6). 277/278 
(99.6%) of unique sgRNA target regions were captured for all samples from this experiment, 
the exception being Arid1a-sg5 (due to unavailability of qualified regions in capture probe 
design). Across all 41 brain and liver samples, the average of mean coverage across all 
probes was 19,405 ± 180 s.e.m. (Table S7). We analyzed the mutant variants at the predicted 
cutting sites of the 277 successfully captured unique sgRNAs across all samples (Methods) 
(Table S8). At the single sgRNA level, for example, at the predicted cutting site of sgRNA-4 
in the Mll2 locus (also known as Kmt2d), various insertions and deletions (indels) were 
detected in AAV-mTSG but not AAV-vector or PBS mice (Figure 3a). As gliomagenesis 
takes multiple months in mice (Figure 1d), we surveyed 3 mice at 3.5 weeks post-injection 
and performed capture sequencing to reveal early mutation profiles, as an approximation for 
in vivo sgRNA cutting efficiency (Figure S4a–b, Table S9). We found that even lower-
efficiency sgRNAs can end up being highly enriched in the process of tumorigenesis if the 
mutations they generated are strongly oncogenic (Figure S4c, Figure 3b–c). After removing 
germline variants, we determined whether the regions flanking each sgRNA target site 
would be classified as significantly mutated sgRNA sites (SMSs) (Methods) (Table S10). We 
implemented a false-discovery-rate (FDR) approach with (FDR < 1/12 PBS/vector samples, 
or 8%) as well as a flat 5% variant frequency cutoff, and confirmed that the choice of 
alternative cutoffs did not alter the final SMS calls (Figure S6a). With these criteria, we 
observed a diverse mutational landscape across most mice that were capture-sequenced 
(Figure 3b–c, Figure S5, Table S11). As an example, one AAV-mTSG mouse (mTSG brain 
10) had significant mutations at the predicted cutting sites of 16 out of 277 captured gene-
targeting sgRNAs in the mTSG library, covering 12 significantly mutated genes (mSMGs) 
(Figure 3b). A second example (mTSG brain 24) showed a more diverse mutational profile 
(34 SMSs for 26 mSMGs) (Figure 3b). The raw indel frequencies were also summed across 
all detected variants for each sgRNA target site in each sample, revealing a highly diverse 
pattern of variant frequencies generated by this sgRNA pool (Figure 3c) (Table S10). 
Comparing brain samples between treatment groups, AAV-mTSG injected brains had 
significantly higher mean variant frequencies (2.087 ± 0.429 s.e.m., n = 25) compared to 
vector (0.005 ± 0.001, n = 3) or PBS (0.003 ± 0.001, n = 4) injected brains (two-tailed 
Welch’s t-test, t24 = 4.85 and t24 = 4.86, p = 6.03 * 10−5 and p = 5.96 * 10−5 for mTSG vs. 
vector and mTSG vs. PBS, respectively) (Figure 3c–d). Comparing targeted vs. non-targeted 
organs in AAV-mTSG injected mice, the mean variant frequencies of brains (2.087 ± 0.429, 
n = 25) were significantly higher than livers (0.309 ± 0.261, n = 4) (two-tailed Welch’s t-
test, t21.48 = 3.54, p = 0.002) (Figure 3c–d). The predominant indels were deletions for 
virtually all samples, and most insertions at SMS sites were 1 bp in size (Figure 3e) (Table 
S8). We identified distinct variant frequency clusters of sgRNA-induced indels that may 
serve as an approximation to the clonality of these tumors (Methods). From this analysis, we 
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found that only 2/22 of the brains had single-cluster tumors, with the majority (20/22) being 
comprised of multiple clusters (Figure S6b). These data demonstrate on-target, pooled 
genome editing in the brain at a library scale, stochastically generating loss-of-function 
mutations in native glial cells and priming them for selection during gliomagenesis.
We next summarized the mutational data from the SMS level to the mSMG level (Table S12) 
and created an oncomap of all mTSG brain samples (Figure 4a). Across all mice with SMGs 
(23/25), the detected variants were predominantly frameshift indels (frameshift reads / total 
variant fraction >60% in 22/23 mice) compared to non-frameshift indels, splicing indels and 
intronic indels (Figure 4A, bottom panel). Surprisingly, all 56 genes have at least one 
associated SMSs, with eight of them (Pten, Map2k4, B2m, Pcna, Cic, Setd2, Gata3 and Apc) 
having 5/5 SMSs (Figure 4a left and middle panel). The SMGs encode functionally diverse 
categories of proteins, including cell death or cell cycle regulators, immunological 
regulators, DNA repair and replication regulators, transcriptional repressors, epigenetic 
regulators, transcription factors, cadherin type proteins and ubiquitin ligases (Figure 4a). 
Many of the genes were significantly mutated in 20% to 50% of mice, with most of the 
epigenetic regulators in this range, such as Arid1b, Mll3, Setd2, Mll2, Kdm5c, Kdm6a, 
Arid2 and Ctcf (Figure 4a), highlighting the role of epigenetic regulators in brain 
tumorigenesis. Interestingly, B2m, a core component of major histocompatibility complex 
(MHC) class I that is essential for antigen presentation, appeared as the second most 
frequently mutated gene (19/25 = 76% of mice) (Figure 4a, right panel). This analysis 
revealed, in a quantitative manner, the relative phenotypic strength of specific loss-of-
function mutations in driving gliomagenesis in vivo.
We compared the mutational frequencies in mice to the variant frequencies of their 
homologous genes in human GBM with their frequencies of non-silent mutation and 
deletion. For these 56 genes, the mutation frequencies in mouse GBMs (an end-product of 
pooled mutagenesis and in vivo gliomagenesis) significantly correlated with the mutation 
frequencies in TCGA GBM patients (Pearson correlation R = 0.402, p = 2.1 * 10−3) (Figure 
4b) (Table S13). To further investigate this correlation, we utilized the clinical cancer 
genomics data from the Yale Glioma tissue bank, a source independent from TCGA (Tables 
S14, S15). Collectively, the mouse mutation frequencies again significantly correlated with 
those in human patients (R = 0.318, p = 0.0277) (Figure 4c) (Table S16). These data suggest 
that the AAV-CRISPR autochthonous GBM mouse model revealed a quantitative phenotypic 
profile of tumor suppressors reflecting the genomic landscape of human GBM patients.
Co-mutation analysis identifies frequently co-occurring driver combinations
To generate an unbiased map of co-drivers, we calculated the co-occurrence rate of double-
mutations for each gene pair (Methods) (Figure 5a–b, Table S17). This analysis showed that 
76 gene pairs out of a total of 1540 possible pairs were statistically significant in terms of 
co-occurrence (hypergeometric test, FDR adjusted q < 0.05). The Nf1+Pten pair emerged as 
the top pair (co-occurrence rate = 18/21 = 85.7%, hypergeometric test, p = 7.53 * 10−8) 
(Figure 5a–c). Interestingly, several previously undocumented combinations emerged, such 
as Kdm5c+Gata3 (co-occurrence rate = 77.8%, hypergeometric test, p = 6.04 * 10−6), and 
B2m+Pik3r1 (70.0%, p = 2.28 * 10−5) (Figure 5a–c). In addition, we performed correlation 
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analysis of summed mutant frequencies for each pair of genes across all mice (Methods) 
(Figure 5d–e, Table S18). 22.9% (352/1540) of the gene pairs were positively correlated 
(Spearman correlation > 0, FDR adjusted q < 0.05) (Figure 5d–e). The most significantly 
correlated gene pair was again Nf1+Pten (Spearman correlation = 0.861, p = 3.34 * 10−8) 
(Figure 5d–f, Table S18), along with other representative pairs such as Cdkn2a+Ctcf 
(correlation = 0.792, p = 2.41 * 10−6) (Figure 5g), B2m+Notch1 (correlation = 0.789, p = 
2.82 * 10−6), and Apc+Pik3r1 (correlation = 0.774, p = 5.77 * 10−6) (Figure 5d–e). 
Exclusion of Trp53 revealed largely identical results for the remaining genes (Figure S7a-b). 
Of note, a subset of the significantly co-occurring pairs were also found to be co-mutated in 
human GBM, including the pairs of RB1+TP53, PTEN+RB1, RASA1+STK11, B2M
+MAP2K4, PTEN+STAG2, CDKN1B+TP53 and CDKN1B+NF1 (Figure S7C–D). These 
data revealed co-occurrence and correlation relationships of specific mutations during 
glioblastoma progression in vivo.
Minipool validation of individual drivers and combinations
We went on to test several of the highly represented individual drivers or combinations using 
an sgRNA minipool validation approach (Methods) (Figure 6a). All of the un-injected (n = 
2), EYFP (n = 4) and empty vector (n = 3) injected mice survived and maintained good body 
condition for the whole duration of the study. Control mice sacrificed from 4 to 11 months 
after treatment were devoid of any observable tumors by histology analysis (Figure 6b, 
Figure S8, Table S19), again indicating that without mutagenesis, or with Trp53 disruption 
alone, LSL-Cas9 mice did not develop brain tumors. In contrast, within 11 months post 
injection, 50% (4/8) of mice receiving AAVs containing Nf1 sgRNA minipool developed 
macrocephaly, poor body condition score and tumors (compared to all 9 control mice, two-
tailed Fisher’s exact test, p = 0.029). All mice receiving Nf1;Pten (9/9, 100%, p = 4.11 * 
10−5) and Nf1;B2m minipools (4/4, 100%, p = 0.0014) developed macrocephaly, poor body 
condition score and large tumors (Figure 6c, Table S19). Notably, mice receiving Nf1;B2m 
minipools had significantly worse survival than mice receiving Nf1 minipools alone (p = 
0.0067) (Figure S9a), implying that loss of antigen presentation in cancer cells likely 
accelerates GBM progression in immunocompetent mice. All mice receiving Rb1, Rb1;Pten, 
or Rb1;Zc3h13 minipools (3/3, 100%, p = 0.0045 for all three groups) developed 
macrocephaly, poor body condition score and large tumors (Figure 6D, Table S19). For the 
same duration of study (maximum 11 months), smaller fractions of mice receiving the AAV 
sgRNA minipools targeting Arid1b;Nf1 (4/9), Mll3;Nf1 (2/5), Mll2 (2/10), Cic (1/5), 
Cic;Pten (1/4), Setd2 (1/5), and Gata3;Mll3 (1/5) developed tumors (Table S19). 
Collectively, half (40/80, or 50%) of the mice receiving AAV sgRNA minipools targeting 
any of the single genes or gene pairs developed brain tumors within 11 months (collective 
validation vs. all controls, two-tailed Fisher’s exact test, p = 0.004). These data indicated 
that mutating these individual genes or combinations in combination with Trp53 causes 
GBM in fully immunocompetent animals.
Interestingly, brain tumors with Nf1 mutations displayed highly polymorphic pathological 
features, with diverse fibroblastic cell morphologies, regions of necrosis and large 
hemorrhages (Figure 6c), yet were almost always GFAP-positive (Figure S8). In sharp 
contrast, tumors with Rb1 mutations were composed of round cells with dense nuclei, 
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frequently with proliferative spindles and giant cells with massive nuclear aneuploidy and 
pleiomorphism, but rarely with regions of necrosis or large-area hemorrhage (Figure 6d), 
and often contained mixtures of GFAP-positive and GFAP-negative cells (Figure S8).
Transcriptomic characterization of tumors with differing mutational backgrounds
We then investigated the molecular underpinnings of gliomagenesis driven by different 
combinations of drivers (Figure 7a, Figure S9b). We performed mRNA-seq to profile the 
transcriptome of these mutant glioma cells (Nf1, Nf1;Mll3, Rb1, and Rb1;Zc3h13, n = 3 cell 
replicates each) (Tables S20, S21). Comparing Nf1-mutant and Rb1-mutant cells, we found 
that 616 genes were more highly expressed in Rb1 cells (Benjamini-Hochberg adjusted p < 
0.05 and log fold change ≥ 1), while 982 genes were more highly expressed in Nf1 cells 
(Figure 7b, Table S22). Gene ontology analysis of the genes associated with higher 
expression in Nf1-mutant cells revealed multiple enriched categories (Benjamini-Hochberg 
adjusted p < 0.05), including extracellular region part, biological adhesion, neuron 
differentiation, hormone metabolic process, cell motion, and cell-cell signaling (Figure 7c). 
Gene ontology analysis of the genes associated with higher expression in Rb1-mutant cells 
revealed a distinct set of enriched categories (adjusted p < 0.05), which surprisingly included 
regionalization, anterior/posterior pattern formation, transcription factor activity, embryonic 
morphogenesis, cell adhesion, extracellular matrix, neuron differentiation, and GTPase 
regulator activity (Figure 7d). Strikingly, a total of 13 Homeobox genes were among the 
top-40 upregulated genes in Rb1 mutants.
To understand the direct effect of additional mutations on the transcriptome of these cells, 
we next compared Nf1;Mll3 to Nf1 cells, and Rb1;Zc3h13 to Rb1 cells. We found that 522 
genes were upregulated in Nf1;Mll3 compared to Nf1 cells, while 175 were downregulated 
(Figure 7e, Table S23). Gene ontology analysis of the upregulated genes in Nf1;Mll3 cells 
revealed enrichment of extracellular matrix, EGF-like region, biological adhesion, calcium 
ion binding, tube development, and growth factor binding (Figure 7f). Comparing 
Rb1;Zc3h13 to Rb1 cells revealed 703 upregulated and 166 downregulated genes (Figure 7g, 
Table S24). Rb1;Zc3h13-high genes were enriched in categories such as extracellular matrix, 
immune response, cell adhesion, 2–5-oligoadenylate synthetase, cell morphogenesis, 
GTPase activity, cell motion, and vasculature development (Figure 7h). Collectively, these 
findings indicate that the addition of an Mll3 mutation significantly alters the transcriptome 
of Nf1 mutant cells, as does the addition of a Zc3h13 mutation on Rb1 mutant cells.
Secondary mutations influence the transcriptome and engender chemotherapeutic 
resistance
As GBM remains a very challenging cancer type to treat, understanding the molecular 
changes underlying drug response is of profound importance. We thus performed drug-
treatment-RNA-seq experiments to investigate the transcriptome responses of AAV-
CRISPR-induced GBM cells (Rb1, Rb1;Pten and Rb1;Zc3h13) to TMZ, a chemotherapeutic 
with significant albeit small survival benefit for GBM patients, among the only 4 currently 
approved drugs for this disease (Methods) (Figure 8a). Drug response phenotyping showed 
that Zc3h13 loss-of-function rendered Rb1 cells significantly more resistant to 1mM TMZ, 
similar to Pten loss-of-function (two-tailed t-test, t4 = 31.32 and t4 = 23.51, p = 6.20 * 10−6 
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and p = 1.94 * 10−5, for Rb1;Pten vs. Rb1 and Rb1;Zc3h13 vs. Rb1, respectively) (Figure 
8b). These differences were also observed with 2mM TMZ (t4 = 50.69 and t4 = 38.10, p = 
9.06 * 10−7 and p = 2.84 * 10−6, for Rb1;Pten vs. Rb1 and Rb1;Zc3h13 vs. Rb1, 
respectively) (Figure 8c). Given the differential responses among these three genotypes, we 
performed mRNA-seq to profile the transcriptome of these mutant cells treated with TMZ as 
compared to DMSO controls (Tables S20, S21). Differential expression analyses of TMZ 
and DMSO treated cells from each of the three genotypes revealed systematic changes in 
gene expression (Figure 8d–f, Table S25–27). Collectively, the differentially expressed genes 
in the TMZ vs. DMSO comparisons uncovered a molecular map of the transcriptomic 
differences between genotypes in response to TMZ treatment (Figure 8g).
Of the genes that were significantly reduced upon TMZ treatment in each group, a total of 
69 genes were shared among all three genotypes (Figure 8h, Table S28), indicating that these 
genes are a common transcriptional response to TMZ. As Rb1;Zc3h13 and Rb1;Pten cells 
exhibited greater survival fractions with TMZ treatment when compared to Rb1 cells, we 
identified 37 genes that were significantly reduced upon TMZ treatment in Rb1;Zc3h13 and 
Rb1;Pten cells, but not in Rb1 cells (Figure 8h, Table S28). As for the genes that were 
significantly induced by TMZ, a total of 42 genes were common in all three genotypes 
(Figure 8i, Table S29), representing a shared TMZ-induced gene signature Interestingly, we 
identified 60 genes that were upregulated upon TMZ treatment in Rb1;Zc3h13 and Rb1;Pten 
cells, but not in Rb1 cells. These included Arl6ip1, which encodes a protein that has been 
shown to suppress cisplatin-induced apoptosis in cancer cells26, and Cd274 (also known as 
PD-L1), which encodes the ligand for the inhibitory receptor PD-1 that is currently a major 
focus of investigation in cancer immunotherapy27. Taken together, the transcriptomic 
analyses provide unbiased molecular signatures underlying the increased TMZ-resistance 
upon Zc3h13 or Pten mutations in Rb1-oncotype glioma cells, suggesting that the precise 
combinations of mutational drivers present in individual GBMs directly influence 
therapeutic responses.
Discussion
To date, there has been no unbiased phenotypic picture of which genetic factors and 
combinations are necessary or sufficient to drive tumorigenesis in the brain. In order to 
answer these questions, it is critical to directly test the hypotheses gleaned from cancer 
genomics in a controlled experimental setting to find causative genes and to quantitatively 
measure their phenotypes in vivo. Determining whether these alterations are bona fide driver 
mutations requires direct in vivo testing, and has historically been performed using cell lines 
or genetically engineered mouse models28. Development and applications of pioneering 
mouse models of GBM have led to profound progress in our understanding of tumor 
initiation, stem cell populations, progression and therapeutic responses of GBM29–40 driven 
by a variety of important mutations. The CRISPR system41–43 has been utilized to directly 
mutate oncogenes and tumor suppressor genes in somatic cells for modeling genetic events 
in various cancer types (reviewed in44). We now demonstrate high-throughput gene editing 
for multiplexed autochthonous GBM models in fully immunocompetent mice. Our study 
provides a massively parallel view of tumor suppressors in vivo, revealing the relative 
selective strength of mutations in these genes when competing in the brain, as well as the 
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driver variations between individuals. As CRISPR targeting might lead to off-target effects 
at other loci, we performed exome sequencing for a subset of the mTSG brain samples. This 
dataset revealed unbiased, exome-wide measurement of other mutations (Figure S7e, Tables 
S30–31). These mutations might be caused by off-target effects of CRISPR, rare AAV 
integrations45, or by the unstable genomes of GBM cells, especially those with p53 loss20, 
throughout tumorigenesis.
Across all genes tested, the mutation frequencies in this highly complex mouse model of 
GBM significantly correlate with the mutation frequencies in human patients from two large 
independent cohorts (TCGA and Yale Glioma bank), suggesting the clinical relevance of the 
findings. Several of the novel SMGs highly enriched in this mouse study have also been 
associated with GBM in the clinical setting, such as B2M, CIC, MLL2, MLL3, SETD2, 
ZC3H13 and ARID1B11, 46–49. Because differences in driver mutations can dramatically 
affect treatment efficacies in pre-clinical animal models and in patients, a functional 
understanding of cancer drivers is therefore essential for precision medicine50.
We also performed a lentiCRISPR direct in vivo screen in GBM, using the same mTSG 
library (Methods, Table S32, Figure S9c–d). We found that the AAV-mTSG CRISPR library 
resulted in more robust gliomagenesis in vivo compared to lentiCRISPR mTSG, in terms of 
latency (death of first animal, 84 vs. 200 days), survival (median survival, 4 vs. 10 months), 
and penetrance (100% vs. 67%). However, AAVs usually do not integrate into the genome, 
except under certain circumstances (low rate of integration at AAVS1 locus)45. Thus, AAV-
encoded transgenes such as exogenously supplied sgRNAs do not replicate as cells divide 
during tumor progression, limiting the readout of the mTSG library by PCR amplification of 
the sgRNA cassette itself. Instead, we achieved successful readout of driver mutations by 
sequencing the predicted sgRNA cutting sites using ultra-deep targeted captured sequencing. 
A key advantage of this approach is the ability to perform high-throughput mutagenesis in 
an autochthonous model of GBM, in which tumors directly evolve from normal cells at the 
organ site in situ in immunocompetent mice, without cellular transplantation. This platform 
can be readily extended to study other types of cancer for tumor progression, as well as 
therapeutic responses in vivo. Taken together, our study provides a systematic and unbiased 
molecular landscape of functional tumor suppressors in an autochthonous mouse model of 
GBM, opening new paths for high-throughput analysis of cancer genetics directly in vivo.
Online Methods
Please see the Life Sciences Reporting Summary for additional information about the 
methods used in this study.
Design, synthesis and cloning of the mTSG library
Briefly, pan-cancer mutation data from 15 cancer types were retrieved from The Cancer 
Genome Atlas (TCGA portal) via cBioPortal51 and Synapse (https://www.synapse.org). 
Significantly mutated genes were calculated similar to previously described methods22–25. 
Known oncogenes were excluded and only known or predicted tumor suppressor genes 
(TSGs) were included. The top 50 TSGs were chosen, and their mouse homologs (mTSG) 
were retrieved from mouse genome informatics (MGI) (http://www.informatics.jax.org). A 
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total of 49 mTSGs were found. A total of 7 known housekeeping genes were chosen as 
internal controls. We designed sgRNAs against these 56 genes using a previously described 
method52, 53 with our custom scripts. Five sgRNAs were chosen for each gene, plus 8 non-
targeting controls (NTCs), making a total 288 sgRNAs in the mTSG library. There were two 
sets of duplicate sgRNAs, Cdkn2a-sg2 / Cdkn2a-sg5, and Rpl22-sg4 / Rpl22-sg5, leaving a 
total of 286 unique sgRNAs.
Design, cloning of an AAV-CRISPR GBM vector and mTSG sgRNA library cloning
An AAV-CRISPR vector was designed for astrocyte-specific genome editing. This vector 
contains a cassette specifically expresses Cre recombinase under the control of a GFAP 
promoter for conditional induction of Cas9 expression in astrocytes in the brain when 
delivered to LSL-Cas9 mice54. Two sgRNA cassettes were built in this vector, one encoding 
an sgRNA targeting Trp53, the most frequently mutated gene in cancer22, 23, 25, with the 
other being an empty sgRNA cassette (double SapI sites for sgRNA cloning) enabling 
flexible targeting of genes of interest in either individual or pooled manner. The vector was 
generated by gBlock gene fragment synthesis (IDT) followed by Gibson assembly (NEB). 
The mTSG libraries were generated by oligo synthesis, pooled, and cloned into the double 
SapI sites of the AAV-CRISPR GBM vector. The library cloning was done at over 100× 
coverage to ensure proper representation. Plasmid library representation was readout by 
barcoded Illumina sequencing as described previously55 with primers customized to this 
vector.
AAV-mTSG viral library production
The AAV-CRISPR GBM plasmid vector (AAV-vector) and library (AAV-mTSG) were 
subjected to AAV9 production and chemical purification. Briefly, HEK 293FT cells 
(ThermoFisher) were transiently transfected with transfer (AAV-vector or AAV-mTSG), 
serotype (AAV9) and packaging (pDF6) plasmids using polyethyleneimine (PEI). Each 
replicate consist of five of 80% confluent HEK 293FT cells in 15-cm tissue culture dishes or 
T-175 flasks (Corning). Multiple replicates were pooled to enhance production yield. 
Approximately 72 hours post transfection, cells were dislodged and transferred to a conical 
tube in sterile PBS. 1/10 volume of pure chloroform was added and the mixture was 
incubated at 37°C and vigorously shaken for 1 hour. NaCl was added to a final concentration 
of 1 M and the mixture was shaken until dissolved and then pelleted at 20k g at 4°C for 15 
minutes. The chloroform layer was discarded while the aqueous layer was transferred to 
another tube. PEG8000 was added to 10% (w/v) and shaken until dissolved. The mixture 
was incubated at 4°C for 1 hour and then spun at 20k g at 4° C for 15 minutes. The 
supernatant was discarded and the pellet was resuspended in DPBS plus MgCl2 and treated 
with Benzonase (Sigma) and incubated at 37°C for 30 minutes. Chloroform (1:1 volume) 
was then added, shaken, and spun down at 12k g at 4C for 15 min. The aqueous layer was 
isolated and passed through a 100 kDa MWCO (Millipore). The concentrated solution was 
washed with PBS and the filtration process was repeated. Virus was titered by qPCR using 
custom Taqman assays (ThermoFisher) targeted to Cre.
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Design, cloning of lentiCRISPR GBM vectors and mTSG sgRNA library, and lentivirus 
production
Two lentiCRISPR vectors were designed, one for constitutive, and the other for astrocyte-
specific genome editing. These vectors contain a cassette specifically expresses Cre 
recombinase under the control of an EFS promoter or a GFAP promoter for conditional 
induction of Cas9 expression in the brain when deliver to LSL-Cas9 mice. Two sgRNA 
cassettes were built in this vector, one encoding an sgRNA targeting Trp53, with the other 
being an empty sgRNA cassette (double BsmbI sites for sgRNA cloning) enabling flexible 
targeting of genes of interest in either individual or pooled manner. These vectors were 
generated by gBlock gene fragment synthesis (IDT) followed by Gibson assembly (NEB). 
The mTSG libraries were generated by oligo synthesis, pooled, and cloned into the double 
BsmbI sites of the lentiCRISPR GBM vectors. The library cloning was done at over 100× 
coverage to ensure proper representation. Plasmid library representation was readout by 
barcoded Illumina sequencing as described above, with primers customized to the vectors. 
The LentiCRISPR GBM plasmid vector (Lenti-vector) and library (Lenti-mTSG) were 
subjected to high-titre lentivirus production and purification. Briefly, HEK 293FT cells 
(ThermoFisher) were transiently transfected with transfer (Lenti-vector or Lenti-mTSG), and 
packaging (psPAX and pMD2.G) plasmids using PEI or Lipofectamine. Each replicate 
consist of five of 80% confluent HEK 293FT cells in 15-cm tissue culture dishes or T-175 
flasks (Corning). Multiple replicates were pooled to enhance production yield. 
Approximately 48 hours post transfection, virus-containing media was collected, and 
purified via sucrose gradient ultracentrifugation at >=30,000 rpm for 2–3h. The supernatant 
was discarded and the pellet was dried and resuspended with 100 μl sterile PBS in 4 °C 
overnight. Virus was titered by viral protein p24 ELISA (RnD).
Animal work statements
All animal work was performed under the guidelines of Yale University Institutional Animal 
Care and Use Committee (IACUC) and Massachusetts Institute of Technology Committee 
for Animal Care (CAC), with approved protocols (Chen-2015-20068, Zhang-0414-024-17, 
and Sharp-0914-091-17), and were consistent with the Guide for Care and Use of 
Laboratory Animals, National Research Council, 1996 (institutional animal welfare 
assurance no. A-3125-01).
Stereotaxic surgery and virus transduction in the mouse brain
Conditional LSL-Cas9 knock-in mice were bred in a mixed 129/C57BL/6 background. 
Mixed gender (randomized males and females) 6–14 week old mice were used in the 
experiment. Animals were maintained and breed in standard individualized cages with 
maximum of 5 mice per cage, with regular room temperature (65–75°F, or 18–23°C), 40–
60% humidity, and a 12h:12h light cycle. Mice were anesthetized by intraperitoneally 
injection of ketamine (100 mg/kg) and xylazine (10 mg/kg), or by inhalation of isoflurane at 
approximately 2% for 20–30 minutes. We also administered buprenorphine HCl (0.1 mg/
kg), or carprofen (5.0 mg/kg) intraperitoneally as a pre-emptive analgesic. Reflexes were 
tested before surgical procedures. Once subject mice were in deep anesthesia, they were 
immobilized in a stereotaxic apparatus (Kopf, or Stoelting) using intra-aural positioning 
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studs and a tooth bar to immobilize the skull. Heat is provided for warmth by a standard 
heating pad, or a heatlamp. According to the mouse brain stereotaxic coordinates56, we 
drilled a 1–2 mm hole on the surface of the skull, and used a 33 G Nanofil syringe needle 
(World Precision Instrument) to inject into the lateral ventricle (LV) at 0.6–1.0 mm caudal/
posterior to Bregma, 0.8–1.5 mm right-side lateral to Bregma, and 2.0–3.0 mm deep from 
the pial surface for injection (coordinates: A/P −0.6 to −1.0, M/L 0.8 to 1.5, D/V −2.0 to 
−3.0). For a small fraction of animals, injections were made into hippocampus (HPF) at the 
following coordinates (A/P −1.3, M/L 0.6, D/V −1.7). PBS, 8 uL AAV (Between 1 × 1010 – 
1× 1011 viral genome copies, or Cre copy number equivalent), or 8 uL lentivirus (Between 8 
× 109 – 8 × 1010 viral particles, or p24 equivalent) was injected into the right hemisphere of 
the brain for each mouse. Injection rates were monitored by an UltraMicroPump3 (World 
Precision Instruments). After injection, the incision site was closed with 6–0 Ethilon sutures 
(Ethicon by Johnson & Johnson), or a VetBond tissue glue (3M). Animal were 
postoperatively hydrated with 1 mL lactated Ringer’s solution (subcutaneous) and housed on 
warmed cages or in a temperature controlled (37°C) environment until achieving ambulatory 
recovery. Meloxicam (1–2 mg/kg) was also administered subcutaneously directly after 
surgery.
MRI
MRI imaging was performed using standard imaging protocol with MRI machines (Varian 
7T/310/ASR-whole mouse MRI system, or Bruker 9.4T horizontal small animal systems). 
Briefly, animals were anesthetized using isoflurane, and setup in the imaging bed with a 
nosecone providing constant isoflurane. A total of 20 – 30 views were acquired for each 
mouse brain using a custom setting: echo time (TE) = 20, repetition time (TR) = 2000, 
slicing = 0.5 mm. Raw image stacks were processed using Osirix or Slicer tools57. 
Rendering and quantification were performed using Slicer (www.slicer.org). For all mice 
with brain tumors, only 1 tumor was observed per mouse. Tumors were approximate as 
spheres and their sizes were calculated with the following formula:
Survival analysis
We observed that mice that developed brain tumors rapidly deteriorate in their body 
condition scores. Mice with observed macrocephaly and body condition score ≤ 1 were 
euthanized and the euthanasia date was recorded as the last survival date. Occasionally mice 
bearing brain tumors died unexpectedly early, and the date of death was recorded as the last 
survival date. Cohorts of mice stereotaxically injected with PBS, AAV-vector or AAV-mTSG 
virus were monitored for their survival. Survival analysis was analyzed using standard 
Kaplan-Meier analysis. Of note, several AAV-vector or PBS injected mice were sacrificed at 
time points earlier than 299 days (at times when a certain AAV-mTSG mice were found dead 
or euthanized due to poor body conditions), to provide time-matched histology, but those 
mice were healthy without brain tumors or other signs of detectable symptoms. Mice 
euthanized early in healthy state were excluded from calculation of survival percentage.
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Mouse brain dissection, fluorescent imaging, and histology
Mice were sacrificed by carbon dioxide asphyxiation or deep anesthesia with isoflurane 
followed by cervical dislocation. Mouse brains were manually dissected under a fluorescent 
stereoscope (Zeiss, Olympus or Leica). Brightfield and/or GFP fluorescent images were 
taken for the dissected brain, and overlaid using ImageJ58. Brains were then fixed in 4% 
formaldehyde or 10% formalin for 48 to 96 hours, embedded in paraffin, sectioned at 6 μm 
and stained with hematoxylin and eosin (H&E) for pathology. For tumor size quantification, 
H&E slides were scanned using an Aperio digital slidescanner (Leica). Tumors were 
manually outlined as region-of-interest (ROI), and subsequently quantified using 
ImageScope (Leica). Sections were de-waxed, rehydrated and stained using standard 
immunohistochemistry (IHC) protocols as previously55, 59. The following commonly used 
antibodies were used for IHC: rabbit anti-Ki67 (abcam ab16667, 1:500), rabbit anti-GFP 
(ThermoFisher Scientific A11122, 1:300) rabbit anti-GFAP (Dako, 1:500), and mouse anti-
Cas9 (Diagenode, 1:300).
Mouse tissue collection for molecular biology
Mouse brain (targeting organ) and liver (non-targeting organ) were dissected and collected 
manually. For molecular biology, tissues were flash frozen with liquid nitrogen, ground in 24 
Well Polyethylene Vials with metal beads in a GenoGrinder machine (OPS diagnostics). 
Homogenized tissues were used for DNA/RNA/protein extractions using standard molecular 
biology protocols.
Genomic DNA extraction from cells and mouse tissues
For genomic DNA (gDNA) extraction, 50–200 mg of frozen ground tissue was resuspended 
in 6 ml of Lysis Buffer (50 mM Tris, 50 mM EDTA, 1% SDS, pH 8) in a 15 ml conical tube, 
and 30 μl of 20 mg/ml Proteinase K (Qiagen) was added to the tissue/cell sample and 
incubated at 55 °C overnight. The next day, 30 μl of 10 mg/ml RNAse A (Qiagen) was 
added to the lysed sample, which was then inverted 25 times and incubated at 37 °C for 30 
minutes. Samples were cooled on ice before addition of 2 ml of pre-chilled 7.5M ammonium 
acetate (Sigma) to precipitate proteins. The samples were vortexed at high speed for 20 
seconds and then centrifuged at ≥ 4,000 × g for 10 minutes. Then, a tight pellet was visible 
in each tube and the supernatant was carefully decanted into a new 15 ml conical tube. Then 
6 ml 100% isopropanol was added to the tube, inverted 50 times and centrifuged at ≥4,000 × 
g for 10 minutes. Genomic DNA was visible as a small white pellet in each tube. The 
supernatant was discarded, 6 ml of freshly prepared 70% ethanol was added, the tube was 
inverted 10 times, and then centrifuged at ≥4,000 × g for 1 minute. The supernatant was 
discarded by pouring; the tube was briefly spun, and remaining ethanol was removed using a 
P200 pipette. After air-drying for 10–30 minutes, the DNA changed appearance from a 
milky white pellet to slightly translucent. Then, 500 μl of ddH2O was added, the tube was 
incubated at 65 °C for 1 hour and at room temperature overnight to fully resuspend the 
DNA. The next day, the gDNA samples were vortexed briefly. The gDNA concentration was 
measured using a Nanodrop (Thermo Scientific).
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Targeted capture sequencing probe design
Targeted capture sequencing probes were designed as following: the predicted cutting sites 
(3bp 5′ of PAM) of the 280 gene-targeting sgRNAs in the mTSG library plus the Trp53-
targeting sgRNA in the vector were retrieved from mouse genome (mm10). The 140bp 
sequences of the flanking regions of the cutting sites (5′- 70bp and 3′- 70bp) were retrieved 
using Bedtools60. The regions were consolidated using NimbleDesign (Roche / NimbleGen), 
and probe matches were set with these parameters (Preferred Close Matches = 3, where 
initial selection of probes for a given region will only include probes with 3 close matches or 
less; and Maximum Close Matches = 20, where if there are insufficient probes available for 
a given region at the Preferred Close Match number, the threshold will be incrementally 
increased to 20 until adequate coverage is achieved. After consolidation, a number of 178 
regions covering 277 sgRNAs, with a total of 33638bp were covered in the probeset, with 
Target Bases Covered = 32239 (95.8%) and one target sgRNA without coverage due to a 
lack of qualified candidate probes in the region.
Targeted capture sequencing
The mTSG-Amplicon targeted capture sequencing probes were synthesized using the 
SeqCap EZ Probe Pool synthesis procedure (Roche). The capture sequencing was done 
following standard Illumina-Roche-Illumina protocols. Genomic DNA samples from mouse 
organs were subjected to fragmentation, followed by a library preparation step using KAPA 
Library Preparation Kit (Illumina). The libraries were then amplified using LM-PCR, 
hybridized to the mTSG-Amplicon probe pool, washed and recovered, and amplified with 
multiplexing barcodes using LM-PCR. The multiplexed library was then QC’ed using 
qPCR, and subjected to high-throughput sequencing using the Hiseq-2500 or Hiseq-4000 
platforms (Illumina) at Yale Center for Genome Analysis. 277/278 (99.6%) of unique 
targeted sgRNAs were captured for all samples from this experiment, with the missing one 
being Arid1a-sg5.
mTSG sgRNA cutting efficiency measurement
The mouse mTSG sgRNA cutting efficiency measurement was performed similar to the 
screen with the exception of early sampling. Briefly, AAV-mTSG library virus was injected 
in to LV of LSL-Cas9 mice, but instead of end-point tumor, mice were sacrificed at early 
time point (3.5 weeks post injection) and examined under fluorescent stereoscope, and GFP
+ regions from the brain were dissected. Genomic DNA was extracted, and subjected to 
capture sequencing.
Mouse whole-exome capture sequencing
The mouse whole-exome capture was performed using SeqCap EZ exome kit (Roche). 
Briefly, capture sequencing was done following standard Illumina-Roche-Illumina protocols. 
Genomic DNA samples from mouse organs were subjected to fragmentation, followed by a 
library preparation step using KAPA Library Preparation Kit (Illumina). The libraries were 
then amplified using LM-PCR, hybridized to the exome probe pool, washed and recovered, 
and amplified with multiplexing barcodes using LM-PCR. The multiplexed library was then 
Chow et al. Page 15
Nat Neurosci. Author manuscript; available in PMC 2018 February 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
QC’ed using qPCR, and subjected to high-throughput sequencing using the Hiseq-2500 or 
Hiseq-4000 platforms (Illumina) at Yale Center for Genome Analysis.
Illumina sequencing data processing and variant calling
FASTQ reads were mapped to the mm10 genome using the bwa mem function in BWA 
v0.7.1361. Bam files were merged, sorted, and indexed using bamtools v2.4.062 and 
samtools v1.363. For each sample, indel variants were called using samtools and VarScan 
v2.3.964. Specifically, we used samtools mpileup (–d 1000000000 –B –q 10), and piped the 
output to VarScan pileup2indel (–min-coverage 1 –min-reads2 1 –min-var-freq 0.001 –p-
value 0.05). To link each indel to the sgRNA that most likely caused the mutation, we took 
the center position of each indel and mapped it to the closest sgRNA cut site.
Calling significantly mutated sgRNAs and significantly mutated genes
We further filtered all detected indels by requiring that each indel must overlap the ± 3 base 
pairs flanking the closest sgRNA cut site, as Cas9-induced double-strand breaks are 
expected to occur within a narrow window of the predicted cut site. We then utilized a series 
of criteria to identify high-confidence mutations: 1) As an initial pass to exclude possible 
germline mutations, we removed any sgRNAs with indels present in more than half of the 
control samples with greater than 5% variant frequency. In our data, this filter specifically 
removed Rps19_sg5 from further consideration. 2) To determine significantly cutting 
sgRNAs in each sample, we used a false-discovery approach based on the PBS and vector 
control samples. For each sgRNA, we first took the highest % variant read frequency across 
all control samples; in order for a mutation to be called in an mTSG sample, the % variant 
read frequency had to exceed the control sample cutoff. However, since the base vector 
contained a Trp53 sgRNA (Trp53 sg8) whose cut site was only 1 bp away from the target 
site of Trp53 sg4 (from mTSG library), we only considered PBS samples when calculating 
the false-discovery cutoff for Trp53 sg4. Nevertheless, in the current study this exception 
was unnecessary because of our third filter: 3) As we were most interested in identifying the 
dominant clones in each sample, we further set a 5% variant frequency cutoff on top of the 
false-discovery cutoff. These criteria gave us a binary table (i.e. not significantly mutated vs. 
significantly mutated) detailing each sgRNA and whether its target site was significantly 
mutated in each sample. None of the AAV-vector samples passed the 5% cutoff at the p53 
sg4/8 target site, which is consistent with our observation that no tumors were found in 
vector-treated animals. To convert significantly cutting sgRNAs into significantly mutated 
genes, we simply collapsed the binary sgRNA scores by gene, such that if any of the 
sgRNAs for a gene were found to be significantly cutting, the gene would be called as 
significantly mutated.
Exome sequencing data analysis
For exome sequencing analysis, we imposed a modified set of criteria on each detected 
variant: 1) ≥ 10 supporting reads for the reference allele; 2) ≥ 10 supporting reads for the 
variant allele; 3) the variant is within ± 6 bp of a Cas9 PAM, NGG (or CCN on the reverse 
strand); 4) a variant allele frequency < 75%, as this was the maximum detected variant 
frequency out of the mTSG brain samples; 5) the variant was not detected in any sequenced 
control samples, which were considered as germline variants.
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Clustering of variant frequencies to infer clonality of tumors
For each mTSG brain sample, we extracted the individual variants that comprised the SMS 
calls in that sample, with a cutoff of 5% variant frequency to eliminate low-abundance 
variants. Because of these cutoffs, 3 sequenced mTSG brain samples were not eligible for 
variant frequency clustering analysis. To identify clusters of variant frequencies in an 
unbiased manner, we modeled the variant frequency distribution with a Gaussian kernel 
density estimate, using the Sheather-Jones method to select the smoothing bandwidth. From 
the kernel density estimate, we then identified the number of local maxima (i.e. “peaks”) 
within the density function. The number of peaks thus represents the number of variant 
frequency clusters for an individual sample, which is an approximation for the clonality of 
the tumors.
Coding frame analysis
For coding frame and exonic/intronic analysis, we only considered the indels that were 
associated with a sgRNA which had been considered significantly mutated in that particular 
sample. This final set of significant indels was converted to .avinput format and 
subsequently annotated using ANNOVAR v. 2016Feb01, using default settings65.
Co-occurrence and correlation analysis
Co-occurrence analysis was performed by first generating a double-mutant count table for 
each pairwise combination of genes in the mTSG library. Statistical significance of the co-
occurrence was assessed by hypergeometric test. For correlation analysis, we first collapsed 
the % variant frequency tables on the gene level (in other words, summing the % variant 
frequencies for all 5 of the targeting sgRNAs for each gene). Using these summed % variant 
frequency values, we calculated the Spearman correlation between all gene pairs, across 
each mTSG sample. Statistical significance of the correlation was determined by converting 
the correlation coefficient to a t-statistic, and then using the t-distribution to find the 
associated probability. A similar approach was used to analyze co-occurring mutations in 
human TCGA GBM data.
Testing driver combinations with sgRNA minipool
Mixtures of five sgRNAs targeting each gene were cloned as sgRNA minipool into the same 
astrocyte-specific AAV-CRISPR vector. For gene pair targeting, the five-sgRNA single gene 
minipools from both genes were mixed 1:1. Plasmid mixes were then packaged into 
AAV1/2. Briefly, HEK293FT cells were transfected with the minipools plasmids, pAAV1 
plasmid, pAAV2 plasmid, helper plasmid pDF6, and PEI Max (Polysciences, Inc. 24765-2) 
in DMEM (ThermoFisher, 10569-010). 72 hours post transfection, cell culture media was 
discarded and cells were rinsed and pelleted via low speed centrifugation. Cells were then 
lysed and the supernatant containing viruses was applied to HiTrap heparin columns (GE 
Biosciences 17-0406-01) and washed with a series of salt solutions with increasing 
molarities. During the final stages, the eluates from the heparin columns were concentrated 
using Amicon ultra-15 centrifugal filter units (Millipore UFC910024). Titering of viral 
particles was executed by quantitative PCR using custom Cre-targeted Taqman probes 
(ThermoFisher). After packaging, AAV minipools were stereotaxically injected into the 
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ventricle of LSL-Cas9 mice. Survival and histology analysis followed injection as described 
above. Several control (uninjected, EYFP and vector) mice were sacrifice as surrogate 
histology although they were in good body condition and were subsequently found devoid of 
tumor.
Generation of Nf1 and Rb1 mutant cell lines from primary GBMs induced by AAV-CRISPR 
minipools
Autochthonous mouse GBMs were induced by stereotaxic injection with the Nf1 or Rb1 
AAV minipool (in the AAV9-sgTrp53-sgX-GFAP-Cre vector described above). Tumor-
containing brains were visually inspected under a fluorescent dissecting scope, made into 
single-cell suspension through physical dissociation plus Collagenase/DNase digestion, and 
cultured in DMEM supplemented with 10% FBS and Pen/Strep. Growing clones were 
further established as autochthonous mouse GBM cell lines.
Single sgRNA knockout lentiviral production
Lenti-pHKO-U6-sgBsmBI-EF1a-Puro-P2A-FLuc was generated by subcloning P2A-Fluc 
expression cassette into lentiviral CRISPR knockout vector by Gibson assembly. For the 
cloning of sgRNA targeting individual genes such as Pten, Arid1b, Mll3 (Kmt2c), B2m, and 
Zc3h13 (Table S1), the corresponding oligos were synthesized, annealed and cloned into 
BsmBI linearized lentiviral knockout vector. Lentiviruses were produced by transfecting 
lentiviral knockout plasmids, together with pMD2.G and psPAX2 into 80–90% confluent 
HEK293FT cells, with viral supernatants collected 48 and 72 h post-transfection, aliquoted 
and stored in −80°C.
Generation of NF1+geneX and RB1+geneX knockout cell lines
The Nf1 and Rb1 knockout tumor cells were infected by single sgRNA knockout 
lentiviruses at M.O.I <= 0.3 to further knockout desired geneX. 24 h post-infection, 
lentiviral transduced cells were selected by the addition of 4–8 μg/ml puromycin and were 
split 2–3 days.
Temozolomide (TMZ) treatment, Cell viability assay, and RNAseq
After 7–9 days’ culture under puromycin selection, lentiviruses-infected Nf1 and Rb1 
knockout tumor cells were plated in triplicates into 96-well plate at a density of 2.5 × 103 
cells per well, and ~5 × 106 cells were collected at the same time and used for cutting 
efficiency analysis. One day after plating, either TMZ or DMSO was added at a 
concentration of 10 μM, 100 μM, 500 μM, 1 mM, and 2 mM. After 3 days of drug/vehicle 
treatment, cell viability was measured using CellTiter Glo (Promega) according to the 
manufactures’ protocol. Briefly, we first equilibrated the CellTiter Glo at room temperature 
for 1 h before use. The media of 96-well plates was aspirated, and then 50 μL fresh DMEM
+10%FBS and 50 μL CellTiter Glo was added. The luminescent signals were readout using 
EnVision plate reader (PerkinElmer). For RNAseq samples preparation, cell lines harboring 
specific gene knockouts were cultured for 7–9 days under the selection pressure of 
puromycin, and then plated into 6-well plates at a density of 2 × 105 cells per well in 
triplicates. 24 h after plating, 1 mM TMZ or DMSO in fresh DEME + 10% FBS was added 
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and cultured for another 48 h. Then, cellular RNA of control or treated cells were extracted 
by adding 350 μL TRIzol Reagent (Invitrogen) directly into 6-well plates to lyse the cells, 
followed by gently shaking the plates and incubation for 5–10 min to complete and lysis and 
homogenization. Then, 70 μL chloroform was added, vigorously mixed, and centrifuged at 
16,000 g for 15 min. Transfer the RNA containing aqueous phase to a new tube and further 
purified using RNeasy mini kit (Qiagen). After eluting RNA from column using Nuclease 
free water, the concentrations of sample RNA were normalized into 150–300 ng/uL for 
RNAseq.
T7 Endonuclease I (T7E1) Assays
The genomic DNA of these cells that were collected after 9 days of puromycin selection was 
extracted by using QuickExtract™ DNA Extraction Solution (Epicentre), mixed well and 
incubated at 65°C for 30–60 min. Then, 1–2 μL of genomic DNA from parental or Lenti-
sgRNA transduced cells was used as the template to amplify gene of interest using surveyor 
primers (Table S33) with thermocycling conditions as 98°C for 1 min, 35 cycles of (98°C for 
1 s, 60°C for 5 s, 72°C for 10 s), and 72°C for 1 min. The PCR products were gel-purified 
using QIAquick Gel Extraction Kit from 2% E-gel EX and quantified, followed by PCR 
products denaturing at 95°C for 5 min, and annealing by using following conditions: ramp 
from 95 to 85 °C at a rate of −2°C per seconds; from 85°C to 25°C at a rate of −0.1°C per 
second, and 4°C hold. 1 μL of T7 endonuclease I was added into annealed oligo, and 
incubated at 37°C for 60 min to digest the mismatched sites. The digested PCR products 
were loaded into 2% E-gel EX, and the amount of DNA fragments were quantified. The 
cutting efficiency was calculated to estimate gene editing using the following formula: 
Indels (%) = 100 × (1 – (1- fraction cleaved)1/2).
Transcriptome profiling of different driver combinations in the presence and absence of 
chemotherapy
Mixtures of five sgRNAs targeting each gene were cloned as sgRNA minipool into the same 
astrocyte-specific AAV-CRISPR vector. After packaging, AAV minipools were 
stereotaxically injected into the lateral ventricle of LSL-Cas9 mice. Cell lines were derived 
from mouse GBMs by single-cell isolation, plating and culture in DMEM media. Additional 
driver mutations were introduced by lentiCRISPR where applicable. GBM cells with 
different drivers were treated with DMSO or TMZ for 48h, and harvested for mRNA-seq for 
transcriptome profiling. Briefly, total RNA was extracted from cancer cells derived from 
AAV-CRISPR minipools induced GBM treated with DMSO or TMZ, using commercially 
available kits (Qiagen / Thermofisher). PolyA-mRNA library was constructed using Illumina 
TruSeq mRNA library prep kit, and sequenced on Illumina Hiseq 2500 and/or Hiseq 4000 
platform.
RNA-seq differential expression analysis
Strand-specific single-end RNA-seq read files were analyzed to obtain transcript level counts 
using Kallisto66, with the settings –rf-stranded -b 100. The counts were subsequently passed 
to the tximport R package to collapse to gene level counts. Pairwise differential expression 
analysis between groups was then performed using edgeR with default settings67.
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Pathway enrichment analysis of differentially expressed transcripts
Using an adjusted p-value cutoff of 0.05, and a log fold change threshold of ±1, we 
determined the set of genes that were significantly upregulated or downregulated. We then 
used the resultant gene sets for DAVID functional annotation analysis68. We considered a 
GO category as statistically significant if the Benjamini-Hochberg adjusted p-value was less 
than 0.05.
GBM comparative cancer genomics analysis using TCGA datasets
Somatic mutation calls, copy number variation calls, RNA-seq expression z-scores, and 
clinical data containing patient survival information were obtained through cBioPortal for 
GBM on November 15, 2016. Pearson correlation coefficients were calculated comparing 
mouse and human mutation frequencies; statistical significance was calculated by converting 
the correlation coefficient to a t-statistic, and then using the t-distribution to calculate 
significance.
GBM comparative cancer genomics analysis using Yale Glioma datasets
Somatic mutation calls and copy number variation calls and partial clinical data containing 
diagnostic information were obtained from Yale Glioma tissue bank and data bank. All 
patient samples were de-identified. The general description, demographics and tumor 
characteristics are noted in the supplemental tables. Total event for each patient was 
calculated as the sum of mutation events and copy number variant events. Pearson 
correlation coefficients were calculated comparing mouse and human mutation frequencies; 
statistical significance was calculated by converting the correlation coefficient to a t-statistic, 
and then using the t-distribution to calculate significance.
Histology analysis of clinical GBM samples from Yale Glioma tissue bank
Histology sections were obtained from Yale Glioma tissue bank. All patient samples were 
de-identified. The mutations associated with specific samples were obtained from Yale 
Glioma data bank. Slides stained with H&E or anti-GFAP were subsequently scanned using 
a slidescanner (Leica) and subjected to pathological analysis.
Statistical tests
In addition to the statistical tests detailed above, we used a two-tailed Welch’s t-test for 
comparisons in which group variances were unequal. If the variances were found to be 
sufficiently equal and the data was normally distributed, we used a standard two-tailed t-test. 
For evaluating differences in the incidence of tumors in different groups, we used Fischer’s 
exact test.
Blinding statement
Investigators were blinded for histology scoring, capture sequencing and RNA-seq 
collection, but not blinded for dissection, MRI, survival analysis, or sequencing analysis.
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Determination of sample sizes
No statistical methods were used to pre-determine sample sizes, but our sample sizes are 
similar to those reported in previous publications cited here.
Code availability
Key custom scripts used to process and analyze the data are included in Supplementary 
Software. Other accessory scripts are available on request.
Data accession
Genomic sequencing (targeted capture, exome) and RNA-seq data have all been deposited in 
NCBI SRA (project PRJNA393202): targeted capture sequencing (SUB2842710), RNA-seq 
(SUB2843781), and exome sequencing (SUB2843864). CRISPR reagents (AAV-CRISPR 
and lentiCRISPR backbone plasmids and mTSG libraries) are available to the academic 
community and have been submitted through Addgene.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Autochthonous brain tumorigenesis induced by an AAV-mediated CRISPR library
(a) Schematics of direct in vivo AAV-CRISPR GBM screen design. Top panel, AAV-mTSG 
library design, synthesis and production. Bottom panel, stereotaxic injection of AAV library 
and subsequent analysis. HPF, hippocampus; LV, lateral ventricle.
(b) MRI sections show brain tumors in AAV-mTSG injected mice, but not in matching 
sections from PBS or AAV-vector injected mice. Arrowheads indicate brain tumors. Scale 
bar, 5 mm.
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(c) MRI-based volumetric quantification of time-matched tumor size ± s.e.m. Two-tailed 
Welch’s t-test, t17 = 2.62, p = 0.018, mTSG vs. vector or PBS (PBS, n = 2 mice; Vector, n = 
6; mTSG, n = 18).
(d) Kaplan-Meier curves for overall survival (OS) of mice injected with PBS (n = 5), AAV-
vector (n = 24) or AAV-mTSG library (n = 56). OS for PBS and vector groups are both 
100%, where the curves are dashed and slightly offset for visibility. Log-rank (LR) test, p < 
2.20 * 10−16, mTSG vs. vector or PBS.
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Figure 2. AAV-mTSG induced brain tumors recapitulate pathological features of GBM
(a) Top panel, representative H&E brain sections from PBS, AAV-vector and AAV-mTSG 
injected mice. Arrowheads indicate brain tumors. Scale bar = 1 mm. Lower panels, 
representative images of brain sections from PBS, AAV-vector and AAV-mTSG injected 
mice stained by Cas9, GFP, GFAP, and Ki67 immunohistochemistry. Cas9 IHC, red 
arrowheads indicate Cas9-positive cells; GFP IHC, red arrowheads indicate GFP-positive 
cells; GFAP IHC, representative GFAP-positive astrocytes in PBS, AAV-vector and AAV-
mTSG injected mice (blue arrows), as well as representative cancer cells in AAV-mTSG 
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injected mice (red arrowheads); Ki67 IHC, arrowheads indicate representative proliferative 
cells, which are mostly in tumors (AAV-mTSG) or scattered in tumor-adjacent brain regions 
(AAV-mTSG). Scale bar = 0.25 mm.
(b) Quantification of tumor sizes ± s.e.m. found in H&E brain sections from PBS, AAV-
vector and AAV-mTSG injected mice. Two-tailed Welch’s t-test, t10 = 3.97, p = 0.003, 
mTSG vs. vector or PBS (PBS, n = 3; Vector, n = 7; mTSG, n = 11).
(c) Representative higher magnification H&E images showing pathological features of AAV-
mTSG induced brain tumors. Clockwise from top left: yellow arrowheads, giant aneuploid 
cells with pleomorphic nuclei; blue arrows, endothelial cells and angiogenesis; green arrows, 
hemorrhagic regions; black arrowheads, necrotic regions. Similar features were observed in 
human GBM patient sections from Yale Glioma tissue bank (Figure S3). Scale bar = 0.5 
mm.
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Figure 3. Targeted captured sequencing of sgRNA sites in AAV-mTSG induced mouse GBM
(a) Indel variants observed at the genomic region targeted by Mll2 sgRNA 4 in 
representative PBS, AAV-vector, and AAV-mTSG injected mouse brain samples.
(b) Bar plots of variant frequencies in significantly mutated sgRNA target regions from two 
representative AAV-mTSG injected mouse brain samples.
(c) Heatmap of variant frequency across all targeted capture samples (n = 41). Rows denote 
individual sgRNAs, while columns correspond to samples from mice stereotaxically injected 
with PBS, AAV-vector, or AAV-mTSG. The liver was considered an off-target organ and 
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thus was used as a background control. Bar plots of the mean variant frequencies for each 
sgRNA (right panel, orange bars) and each sample (bottom panel, purple bars) are shown.
(d) Dot plot of mean variant frequency ± s.e.m., grouped by treatment condition and tissue 
type. AAV-mTSG injected brains had significantly higher mean variant frequencies (2.087 
± 0.429, n = 25) compared to vector (0.005 ± 0.001, n = 3) or PBS (0.003 ± 0.001, n = 4) 
injected brains (two-tailed Welch’s t-test, t24 = 4.85 and t24 = 4.86, p = 6.03 * 10−5 and p = 
5.96 * 10−5 for mTSG vs. vector and mTSG vs. PBS). Comparing brain vs. liver in AAV-
mTSG injected mice, mean variant frequencies of brains (2.087 ± 0.429) were significantly 
higher than livers (0.309 ± 0.261, n = 4) (t21.48 = 3.54, p = 0.002).
(e) Indel size distribution for all filtered variants in each mTSG brain sample (n = 25).
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Figure 4. Integrative analysis of functional mutations in driving tumorigenesis
(a) Gene-level mutational landscape of AAV-mTSG induced primary mouse GBM.
Center: Tile chart depicting the mutational landscape of primary brain samples from LSL-
Cas9 mice injected with the AAV-mTSG library (n = 25), AAV-vector (n = 3) or PBS (n = 
4). Genes are grouped and colored according to their functional classifications as noted in 
the top-right legend.
Top: Bar plots of the total number of significantly mutated genes identified in each AAV-
mTSG sample.
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Right: Bar plots of the percentage of GBM samples that were called as significantly mutated 
for each gene.
Left: Heatmap of the numbers of unique significantly mutated sgRNAs (SMSs) for each 
gene.
Bottom: Stacked bar plots describing the type of indels observed in each sample, colored 
according to the bottom-right legend.
(b–c) Comparative cancer genomics in GBM using the TCGA (b) and Yale Glioma (c) 
datasets. Scatterplot of population-wide mutant frequencies for the genes in the mTSG 
library, comparing AAV-mTSG treated mouse brain samples to human samples. 
Representative strong drivers in both species are labeled, with gene names color-coded based 
on their functional classification (as in a).
(b) Mutant frequencies in AAV-mTSG treated mouse brain samples correlated with patients 
in the TCGA GBM dataset (Pearson correlation R = 0.402, p = 0.002).
(c) Mutant frequencies in AAV-mTSG treated mouse brain samples correlated with patients 
in the Yale Glioma dataset (Yale Glio) (Pearson correlation R = 0.318, p = 0.028).
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Figure 5. Co-mutation analysis uncovers synergistic gene pairs in GBM
(a) Upper-left half: heatmap of pairwise mutational co-occurrence rates. Lower-right half: 
heatmap of -log10 p-values by hypergeometric test for statistical co-occurrence.
(b) Scatterplot of the co-occurrence rate of each gene pair, plotted against −log10 p-values.
(c) Venn diagrams showing representative strongly co-occurring mutated gene pairs such as 
Kdm5c and Gata3 (co-occurrence rate = 77.8%, hypergeometric test, p = 6.04 * 10−6), B2m 
and Pik3r1 (70.0%, p = 2.28 * 10−5), as well as Nf1 and Pten (85.7%, p = 7.53 * 10−8).
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(d) Upper-left half: heatmap of the pairwise Spearman correlation of variant frequency for 
each gene, summed across sgRNAs. Lower-right half: heatmap of −log10 p-values to 
evaluate the statistical significance of the pairwise correlations.
(e) Scatterplot of pairwise Spearman correlations plotted against −log10 p-values.
(f–g) Scatterplots showing representative strongly correlated gene pairs when comparing 
variant frequencies summed across sgRNAs, such as Nf1+Pten (f) and Cdkn2a+Ctcf (g). 
Spearman correlation coefficients are noted on the plot.
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Figure 6. Validation of driver combinations
(a) Schematic representation of experiment design. Mixtures of five sgRNAs targeting each 
gene were cloned as minipools into the astrocyte-specific AAV-CRISPR vector. After 
packaging, AAV minipools were stereotaxically injected into the lateral ventricle of LSL-
Cas9 mice.
(b–e) End-point histology (H&E) of representative brain sections from mice treated with 
AAV sgRNA minipools or relevant controls. In this end-point analysis, mice were 
euthanized when either macrocephaly or poor body condition score (< 2) was observed, with 
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survival time ranging from 3 to 11 months. Treatments are indicated to the left of each 
image. Arrowheads indicate the presence of brain tumors. The proportion of tumor-bearing 
to total mice is indicated in the top right corner of the images. Scale bar = 0.5 mm.
(b) Representative histology of brain sections from control mice. No tumors were observed 
in mice from the vector (0/3), EYFP (0/4) or uninjected (0/2) groups.
(c) Representative histology of brain sections from mice treated with various Nf1 minipools, 
such as Nf1 alone (4/8 mice developed tumors within 11 months), Nf1;Pten (9/9 mice 
developed tumors within 6 months), Nf1;Mll3 (2/5 mice developed tumors within 6 months), 
and Nf1;B2m (4/4 mice developed tumors within 11 months).
(d) Representative histology of brain sections from mice treated with various Rb1 minipools, 
such as Rb1 alone (3/3 mice developed tumors within 6 months), Rb1;Zc3h13 (3/3 mice 
developed tumors within 6 months), and Rb1;Pten (3/3 mice developed tumors within 6 
months).
(e) Representative histology of brain sections from mice treated with other minipools, such 
as Mll2 alone (2/10 mice developed tumors within 11 months), Setd2 (1/5 mice developed 
tumors within 6 months), and Cic (1/5 mice developed tumors within 6 months).
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Figure 7. Transcriptional profiling of mouse GBM driver combinations
(a) Schematic of mouse GBM RNA-seq experimental design. Rb1 or Nf1 AAV minipools 
were stereotaxically injected into the lateral ventricle of LSL-Cas9 mice. Cell lines were 
derived from mouse GBMs by single-cell isolation. Additional driver mutations were 
introduced by lentiCRISPR where applicable. Cells were then transcriptionally profiled by 
RNA-seq (n = 3 samples per condition).
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(b) Volcano plot comparing gene expression profiles in Rb1 mutant (red) to Nf1 mutant 
(blue) GBM cells. 616 genes were significantly higher in Rb1 cells, and 982 genes were 
significantly higher in Nf1 cells
(c) Enriched gene ontology categories among Nf1-high genes.
(d) Enriched gene ontology categories among Rb1-high genes.
(e) Volcano plot comparing Nf1;Mll3 mutant (orange) to Nf1 mutant (blue) GBM cells. 522 
genes were significantly higher in Nf1;Mll3 cells, and 175 genes were significantly higher in 
Nf1 cells.
(f) Enriched gene ontology categories among Nf1;Mll3-high genes.
(g) Volcano plot comparing Rb1;Zc3h13 mutant (green) to Rb1 mutant (red) GBM cells. 703 
genes were significantly higher in Rb1;Zc3h13, and 166 genes were significantly higher in 
Rb1 cells.
(h) Enriched gene ontology categories among Rb1;Zc3h13-high genes.
Differentially expressed genes were defined as Benjamini-Hochberg adjusted p < 0.05 and 
log fold change ≥ 1 or ≤ −1.
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Figure 8. Transcriptional profiling of mouse GBM driver combinations in the presence and 
absence of a chemotherapeutic agent
(a) Schematic of drug treatment RNA-Seq experimental design. Rb1, Rb1;Pten, and 
Rb1;Zc3h13 GBM cells were treated with either temozolomide (TMZ) or DMSO. Cells 
were then subjected to phenotypic analysis and RNA-seq.
(b–c) Survival fraction ± s.e.m of Rb1 (blue), Rb1;Pten (purple), and Rb1;Zc3h13 (green) 
cells with 1 mM (b) or 2 mM (c) TMZ treatment. Individual cell replicates are shown (n = 3 
for all conditions).
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(b) Rb1;Pten and Rb1;Zc3h13 cells had significantly higher survival fractions than Rb1 cells 
with 1 mM TMZ (two-sided t-test,p = 6.20 * 10−6 and p = 1.94 * 10−5, respectively).
(c) Rb1;Pten and Rb1;Zc3h13 cells had significantly higher survival fractions than Rb1 cells 
with 2 mM TMZ (two-sided t-test, p = 9.06 * 10−7 and p = 2.84 * 10−6, respectively). 
Individual cell replicates are shown (n = 3 for all conditions).
(d) Volcano plot comparing Rb1 cells treated with TMZ (dark blue) or DMSO (blue). 352 
genes were significantly higher in TMZ-treated cells (TMZ-induced genes), and 332 genes 
were significantly higher in DMSO-treated cells (TMZ-reduced genes).
(e) Volcano plot comparing Rb1;Pten cells treated with TMZ (pink) or DMSO (purple). 345 
genes were significantly higher in TMZ-treated cells, and 313 genes were significantly 
higher in DMSO-treated cells.
(f) Volcano plot comparing Rb1;Zc3h13 cells treated with TMZ (turquoise) or DMSO 
(green). 703 genes were significantly higher in TMZ-treated cells, and 166 genes were 
significantly higher in DMSO-treated cells
(g) Heatmap of all differentially expressed genes among the TMZ vs. DMSO comparisons. 
Clustering was performed by average linkage using Pearson correlations. Values are shown 
in terms of z-scores, scaled by each gene.
(h) Venn diagram of TMZ-reduced genes for each tested genotype. While 69 genes were 
similarly downregulated among all 3 genotypes upon TMZ treatment, the differential 
expression signatures were nevertheless distinct, suggesting differential responses to TMZ 
treatment.
(i) Venn diagram of TMZ-induced genes for each tested genotype. Though 42 genes were 
consistently upregulated in all 3 groups upon TMZ treatment, numerous transcriptional 
differences were nevertheless apparent, suggesting differential responses to TMZ treatment.
Differentially expressed genes were defined as Benjamini-Hochberg adjusted p < 0.05 and 
log fold change ≥ 1 or ≤ −1.
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